Again......there is no such thing as a "consenus" in clinical trials. The phase II study (89 patients) had a 41% PASI-75. A 33% PASI-75 for a much larger phase III study is very, very good (placebo was 5%). You can not compare this drug to Enbrel as Enbrel has significantly more serious side effects. The primary endpoint was in fact met (p
The primary endpoint of the phase III trial was made, not missed. The drug will definitely win FDA approval in psoriasis, and will take significant market share from the biologics, which come with side effect liabilities and are injectables.